Signaturefd, LLC Crinetics Pharmaceuticals, Inc. Transaction History

Signaturefd, LLC

$5.8 Billion
Q3 2025

A detailed history of Signaturefd, LLC transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Signaturefd, LLC holds 388 shares of CRNX stock, worth $16,555. This represents 0.0% of its overall portfolio holdings.

Number of Shares

388

Previous 297 30.64%

Holding current value

$16,555

Previous $8,000 100.0%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Oct 21, 2025	BUY	$26.85 - $45.91 $2,443 - $4,177	91 Added 30.64%	388 $16,000
Q2 2025 Jul 16, 2025	SELL	$25.56 - $33.76 $1,661 - $2,194	-65 Reduced 17.96%	297 $8,000
Q1 2025 May 01, 2025	SELL	$32.3 - $53.15 $3,779 - $6,218	-117 Reduced 24.43%	362 $12,000
Q2 2024 Jul 29, 2024	BUY	$42.12 - $51.91 $7,328 - $9,032	174 Added 57.05%	479 $21,000
Q1 2024 May 03, 2024	BUY	$34.76 - $46.81 $139 - $187	4 Added 1.33%	305 $14,000
Q4 2023 Jan 31, 2024	SELL	$25.62 - $37.07 $5,124 - $7,414	-200 Reduced 39.92%	301 $10,000
Q3 2023 Nov 03, 2023	BUY	$15.97 - $30.59 $3,481 - $6,668	218 Added 77.03%	501 $14,000
Q2 2023 Aug 01, 2023	SELL	$15.73 - $23.6 $235 - $354	-15 Reduced 5.03%	283 $5,000
Q1 2023 Apr 28, 2023	BUY	$15.31 - $21.1 $107 - $147	7 Added 2.41%	298 $4,000
Q4 2022 Jan 27, 2023	SELL	$15.49 - $19.05 $1,641 - $2,019	-106 Reduced 26.7%	291 $5,000
Q3 2022 Nov 08, 2022	BUY	$18.11 - $22.37 $2,064 - $2,550	114 Added 40.28%	397 $8,000
Q1 2022 May 02, 2022	SELL	$17.15 - $28.31 $651 - $1,075	-38 Reduced 11.84%	283 $6,000
Q3 2021 Oct 28, 2021	BUY	$16.88 - $25.23 $641 - $958	38 Added 13.43%	321 $7,000
Q4 2020 Feb 11, 2021	BUY	$12.08 - $17.46 $3,418 - $4,941	283 New	283 $4,000

Others Institutions Holding CRNX

# of Institutions

248

Shares Held

93.6M

Call Options Held

695K

Put Options Held

80.6K

View Full List

About Crinetics Pharmaceuticals, Inc.

Ticker CRNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,752,800
Market Cap $2.29B
Description
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...

More about CRNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Signaturefd, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Signaturefd, LLC with notifications on news.

Account